The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial.
Publication/Presentation Date
2-1-2022
Abstract
AIMS: N-terminal pro-b-type natriuretic peptide (NT-proBNP) values may be influenced by patient factors beyond the severity of illness, including atrial fibrillation (AF), renal dysfunction, or increased body mass index (BMI). We hypothesized that these factors may influence the achievement of NT-proBNP targets and clinical outcomes.
METHODS: A total of 894 patients with heart failure with reduced ejection fraction were enrolled in The Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment trial. NT-proBNP was analysed every 3 months.
RESULTS: Forty per cent of patients had AF, the median estimated glomerular filtration rate (eGFR) was 59 mL/min/1.73 m
CONCLUSIONS: Patients with AF, a lower BMI, or worse renal function are less likely to achieve a lower or target NT-proBNP. Clinicians should be aware of these factors both when interpreting NT-proBNP levels and making therapeutic decisions about heart failure therapies.
Volume
9
Issue
1
First Page
77
Last Page
86
ISSN
2055-5822
Published In/Presented At
Ezekowitz, J. A., Alemayehu, W., Rathwell, S., Grant, A. D., Fiuzat, M., Whellan, D. J., Ahmad, T., Adams, K., Piña, I. L., Cooper, L. S., Januzzi, J. L., Leifer, E. S., Mark, D., O'Connor, C. M., & Felker, G. M. (2022). The influence of comorbidities on achieving an N-terminal pro-b-type natriuretic peptide target: a secondary analysis of the GUIDE-IT trial. ESC heart failure, 9(1), 77–86. https://doi.org/10.1002/ehf2.13692
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
34784657
Department(s)
Administration and Leadership
Document Type
Article